Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect our current expectations as to future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. These statements include, but are not limited to, statements under the heading, "Fiscal 2025 Outlook," "Modeling Assumptions," and those related to our expectation ...

Financial Performance - Harmony Biosciences reported Q2 2025 net product revenue of $200.5 million, a 16% year-over-year increase compared to $172.8 million in Q2 2024 [8, 36] - The company's non-GAAP adjusted net income for Q2 2025 was $53.8 million, a 120% increase from $24.5 million in Q2 2024 [36] - Harmony Biosciences is confirming its full-year 2025 revenue guidance of $820 million to $860 million [8] - Cash, cash equivalents, and investments totaled $672.3 million as of Q2 2025, compared to $434.1 million in Q2 2024, a 55% increase [6, 38] WAKIX Performance - WAKIX is approaching blockbuster status, representing a $1 billion opportunity in narcolepsy alone [9] - The average patient count for WAKIX grew by approximately 400 to approximately 7,600 patients [8] - WAKIX has strong payer coverage of >80% of lives [8] Pipeline Development - Harmony Biosciences plans to initiate Phase 3 registrational trials for Pitolisant HD in narcolepsy and idiopathic hypersomnia (IH) in Q4 2025 [17, 29] - Topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X Syndrome (FXS) is expected in Q3 2025 [17, 18] - EPX-100 Phase 3 registrational trials are ongoing in Dravet syndrome (ARGUS study) & Lennox-Gastaut syndrome (LIGHTHOUSE study), with topline data anticipated in 2026 [17, 33]

Operational Milestones - Vertical Aerospace is on track to meet every communicated target toward Flightpath 2030[16] - The company successfully completed a 15.2-meter battery pack drop test and full-scale thermal runaway propagation test in April 2025[21] - Vertical Aerospace is initiating production with long-range parts purchasing[18] Strategic Partnerships - Bristow upsizing pre-order option to purchase up to 50 more aircraft[41] - Vertical Aerospace announced a partnership with Bristow on June 12, 2025, to provide a "Ready-to-fly" model to Vertical's customers[45] Financial Status - As of June 30, 2025, Vertical Aerospace had £62 million / $85 million in cash and cash equivalents[54] - After a July 2025 fundraise of £52 million / $69 million (gross proceeds), the company's cash position was £104 million / $137 million as of August 5, 2025[54] - Post-July fundraise, Vertical is funded through to the middle of 2026[54] Order Book - Vertical Aerospace has pre-orders for up to 200 aircraft[40] - Avolon has placed orders for at least 100 aircraft and up to 250 aircraft[40] - Other partners have placed orders for up to 500 aircraft, up to 100 aircraft, up to 100 aircraft, up to 50 aircraft, and up to 50 aircraft[40]

Second Quarter 2025 Financial Results Conference Call Presentation August 5, 2025 Together, Building the Future Safe Harbor Statement 3 Key Priorities This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions with respect to the future and Uniti management's current expectations, involve certain risks and uncertainties, and are not guarantees. These forward-looking statements include, ...

Financial Performance - Second quarter revenue reached $19993 thousand, a 75% increase year-over-year compared to $11430 thousand in the second quarter of 2024[12] - The company's GAAP gross margin was -196% in the second quarter of 2025, compared to -205% in the second quarter of 2024[12] - Non-GAAP gross margin was -174% in the second quarter of 2025, compared to -168% in the second quarter of 2024[12] - GAAP net loss was $15430 thousand in the second quarter of 2025, compared to $12241 thousand in the second quarter of 2024[12] - Non-GAAP net loss was $11213 thousand in the second quarter of 2025, compared to $10730 thousand in the second quarter of 2024[12] Outlook for Third Quarter 2025 - The company expects revenue to be between $18 million and $24 million[13] - Non-GAAP gross profit is projected to be between -$24 million and -$06 million[13] - Non-GAAP gross margin is expected to range from -134% to 25%[13] - Adjusted EBITDA is forecasted to be between -$108 million and -$68 million[13]

Financial Performance - Consolidated revenue increased by 70% to $403 million[13] - Adjusted EBITDA rose by 77% to $129 million[13] - AFFO increased significantly by 759% to $28 million[13] - America segment revenue increased by 44% to $303 million[14] - Airports segment revenue increased significantly by 156% to $100 million[17] Segment Highlights - America's digital revenue grew by 111% to $114 million[16] - Airports' digital revenue increased by 315% to $64 million[19] - Site lease expense for America increased by 111% to $94 million[16] - Site lease expense for Airports increased by 134% to $60 million[19] Capital Structure - Debt decreased by $226 million, reaching $5067 billion[24]

Q2 2025 EARNINGS | August 5, 2025 DISCLAIMER Certain statements in this presentation may constitute "forward-looking" statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events, including, without limitation, statements regarding future financial or operating performa ...

Financial Performance - Revenue was $1.6 billion, down 1% ex-FX, consistent with the phasing of the Loss of Exclusivity (LOE) of Atozet[12] - Adjusted EBITDA was $522 million, representing a 32.7% Adjusted EBITDA margin[12] - The company raised full-year 2025 revenue guidance by $100 million at the midpoint, while the Adjusted EBITDA range was affirmed[12] - The company repaid $345 million of long-term debt and is on track to achieve net leverage below 40x by year-end[12] - Adjusted Gross Margin was 617% for both Q2 2025 and YTD 2025, compared to 620% for Q2 2024 and YTD 2024[30] Segment Performance - Women's Health revenue increased by 3% to $462 million in Q2 2025, and 6% YTD to $925 million[14] - Biosimilars revenue increased by 5% to $173 million in Q2 2025, but decreased 6% YTD to $314 million[18] - Established Brands revenue decreased by 3% to $936 million in Q2 2025, and 7% YTD to $1822 billion[23] Product Performance - Nexplanon revenue decreased 1% to $240 million in Q2 2025, but increased 6% YTD to $488 million[14] - Follistim AQ revenue increased 18% to $74 million in Q2 2025, and 31% YTD to $142 million[14] - Hadlima revenue increased 78% to $50 million in Q2 2025, and 66% YTD to $96 million[18]

Clear Channel Outdoor Holdings 2025 Second Quarter Results August 5, 2025 Safe harbor statement and other information Forward-Looking Statements Certain statements in this presentation are considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Clear Channel Outdoor Holdings, Inc. and its subsidiaries ( ...

The results of operations data contained in this presentation are based on our preliminary, unaudited results of operations for the quarter ended June 30, 2025. Such preliminary data should not be viewed as a comprehensive statement of our financial results for the quarter ended June 30, 2025 CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS August 5, 2025 Disclaimers 2Q25 Earnings Presentation The forward-looking statements contained in this presentation are based on our current expectations and belie ...